Can-Fite Biopharma Ltd ADR (CANF) Stock Price, Quote & News

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 924 1114

Fax: 972 3 924 9378

Website: www.canfite.com

Address:

26 Ben Gurion Street, Ramat Gan, Israel

GeeJoon Feb. 18 at 1:25 PM

$CANF thanks god that 5% sabby shorters has SOLD ALL

0 · Reply

__ReversalTrackers Feb. 18 at 12:26 PM

$MLEC $ICU $CANF $BVC _

0 · Reply

GeeJoon Feb. 18 at 9:24 AM

$CANF over 40% inst holding, wrong data? Can-Fite BioPharma Ltd. - Depositary Receipt (Common Stock) (US:CANF) has 17 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 596,567 shares. Largest shareholders include Rhumbline Advisers, Jane Street Group, Llc, Advisor Group Holdings, Inc., UBS Group AG, XTX Topco Ltd, Bogart Wealth, LLC, Two Sigma Securities, Llc, Fifth Third Bancorp, Wells Fargo & Company/mn, and Costello Asset Management, INC

0 · Reply

GeeJoon Feb. 18 at 8:19 AM

$CANF the only 5% holder Sabby Management sold all, not good

0 · Reply

GeeJoon Feb. 18 at 2:59 AM

$CANF canf has been doing a great job to maintain the pipelines over 20 years which is nearly impossible for a micro biopharm without gov grant or upfront payment, unfortunately the CEO is not planning to sell the company, no resources no progress, look at Takeda's Zasocitinib, 33% psoriasis patients were clear in only 12 weeks, although acquired from other biopharm, started the trial later than Piclidenoson, but now Takeda is going to submit NDA in 2026

0 · Reply

translucide Feb. 17 at 6:29 PM

$CANF According to the news today, the weight loss on mices was much better than Ozempic.... if this is replicated on humans it makes this company even more undervalued that it is already. This study has found 6% body weight loss in 4 weeks in mices, and Ozempic achieves this in 3 months. CANF study : https://www.nature.com/articles/s41366-026-02017-2.epdf?sharing_token=mRCG1QKpJkT5e8H25Fc96tRgN0jAjWel9jnR3ZoTv0Nyw1aSzV76OEax1oupt_jdi8A7A8bAMZwEUN9e-Q3w-iej4mnj8Ja85lpDJntXhCBam55akNq3L8zjHA1V1OopN5tjSzCOVmm4-K6LB7Y9sPufGVc4lVtpbxIeHIPEemM%3D Ozempic reference for body mass loss : https://pmc.ncbi.nlm.nih.gov/articles/PMC9486455/

1 · Reply

__ReversalTrackers Feb. 17 at 12:42 PM

$CANF $BVC $RVYL ✓

0 · Reply

TheTradeXchange Feb. 17 at 12:01 PM

$CANF - Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson

0 · Reply

Danypoopoo Feb. 17 at 12:01 PM

$CANF 🥱 https://ir.canfite.com/news-events/press-releases/detail/1104/can-fite-announces-scientific-breakthrough-publication

0 · Reply

TrendEli Feb. 17 at 8:55 AM

$CANF Pre-revenue biotech; early-stage

0 · Reply

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

Dec 16, 2025, 9:19 AM EST - 2 months ago

Can-Fite Provides Update on Clinical and Financial Status

Nov 20, 2025, 7:00 AM EST - 3 months ago

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

Aug 28, 2025, 8:47 AM EDT - 6 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Jul 30, 2025, 7:04 AM EDT - 7 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Jul 28, 2025, 12:24 PM EDT - 7 months ago

Can-Fite Announces Up To $15.0 Million Public Offering

Jul 28, 2025, 7:00 AM EDT - 7 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Apr 17, 2025, 8:55 AM EDT - 10 months ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Apr 14, 2025, 2:28 PM EDT - 11 months ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Mar 20, 2025, 9:45 AM EDT - 11 months ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Mar 19, 2025, 9:00 AM EDT - 1 year ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mar 3, 2025, 6:00 AM EST - 1 year ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Feb 10, 2025, 7:10 AM EST - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Feb 5, 2025, 7:00 AM EST - 1 year ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Dec 30, 2024, 7:00 AM EST - 1 year ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SXTP

Nov 11, 2024, 7:00 AM EST - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Nov 4, 2024, 7:08 AM EST - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Oct 18, 2024, 9:06 AM EDT - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Oct 9, 2024, 7:00 AM EDT - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Aug 29, 2024, 8:15 AM EDT - 1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 9, 2024, 9:00 AM EDT - 1 year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Aug 8, 2024, 7:01 PM EDT - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Provides Namodenoson Patent Update

Jul 17, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

May 29, 2024, 7:00 AM EDT - 1 year ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 27, 2024, 7:00 AM EDT - 1 year ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 23, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 13, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 10, 2024, 9:00 AM EDT - 1 year ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

May 9, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 6, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Feb 28, 2024, 7:00 AM EST - 2 years ago

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Jan 30, 2024, 7:00 AM EST - 2 years ago

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Jan 29, 2024, 7:00 AM EST - 2 years ago

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Dec 20, 2023, 7:00 AM EST - 2 years ago

The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Dec 4, 2023, 7:00 AM EST - 2 years ago

Can-Fite's Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Nov 30, 2023, 7:00 AM EST - 2 years ago

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

GeeJoon Feb. 18 at 1:25 PM

$CANF thanks god that 5% sabby shorters has SOLD ALL

0 · Reply

__ReversalTrackers Feb. 18 at 12:26 PM

$MLEC $ICU $CANF $BVC _

0 · Reply

GeeJoon Feb. 18 at 9:24 AM

0 · Reply

GeeJoon Feb. 18 at 8:19 AM

$CANF the only 5% holder Sabby Management sold all, not good

0 · Reply

GeeJoon Feb. 18 at 2:59 AM

0 · Reply

translucide Feb. 17 at 6:29 PM

1 · Reply

__ReversalTrackers Feb. 17 at 12:42 PM

$CANF $BVC $RVYL ✓

0 · Reply

TheTradeXchange Feb. 17 at 12:01 PM

$CANF - Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson

0 · Reply

Danypoopoo Feb. 17 at 12:01 PM

$CANF 🥱 https://ir.canfite.com/news-events/press-releases/detail/1104/can-fite-announces-scientific-breakthrough-publication

0 · Reply

TrendEli Feb. 17 at 8:55 AM

$CANF Pre-revenue biotech; early-stage

0 · Reply

EvanCole_Trading1 Feb. 16 at 6:34 PM

Tuesday watchlist: $MLEC $OLB $JDZG $CANF $ATOM.X

1 · Reply

terrapin22 Feb. 16 at 1:04 AM

$CANF

0 · Reply

GeeJoon Feb. 16 at 12:55 AM

$CANF the fintel data seems wrong, the shares counting is still using the ratio pre rs, so the correct numbers should be divided by 20

0 · Reply

GeeJoon Feb. 14 at 12:04 PM

$CANF wall street is entering...

0 · Reply

GeeJoon Feb. 14 at 1:52 AM

$CANF Jane Street Group is no joke, wall street may be buying slowly

0 · Reply

EvanCole_Trading1 Feb. 14 at 12:50 AM

Tuesday watchlist: $MLEC $OLB $JDZG $CANF $ATOM.X

0 · Reply

EvanCole_Trading1 Feb. 13 at 8:03 PM

Afterhours + Monday watchlist: $MLEC $OLB $JDZG $CANF $ATOM

0 · Reply

watchaddict Feb. 13 at 1:33 PM

$CANF adding

0 · Reply

GeeJoon Feb. 13 at 11:05 AM

$CANF The most profit firm of wall street Jane Street Group, Llc just acquired 205,004 shares, very bullish

1 · Reply

GeeJoon Feb. 12 at 12:57 AM

$CANF seems like this drug is much effective on psoriasis and will submit NDA in 2026 https://www.takeda.com/newsroom/newsreleases/2025/takeda-zasocitinib-phase-3-plaque-psoriasis-data-once-daily-pill/

0 · Reply

Tryingtoretire01 Feb. 10 at 4:31 PM

$CANF AI Overview Can-Fite BioPharma (CANF) is considered a high-risk, high-reward, speculative biotech stock with a "Strong Buy" consensus among analysts, featuring massive, albeit highly speculative, upside potential based on pipeline progress for its drugs Namodenoson and Piclidenoson. While recent clinical results are promising, it remains a micro-cap, volatile stock that may not suit conservative investors. Key Considerations for CANF Stock: Analyst Outlook: Analysts maintain a "Strong Buy" rating with high price targets (ranging from $50–$90), representing significant, though highly speculative, upside from current levels.

0 · Reply

Erikg19 Feb. 10 at 6:29 AM

$CANF What's the O/S 'converted' to shares in the US? I'm only seeing what the numbers are on the OTCBB site.

1 · Reply

Market Cap	5.93M
Revenue (ttm)	670,000.00
Net Income (ttm)	-7.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,176.12%
Debt to Equity Ratio	0.00

Volume	11,052
Avg Vol	260,277
Day's Range	N/A - N/A
Shares Out	1.31M
Stochastic %K	54%
Beta	1.07
Analysts	Sell
Price Target	$70.00